45th Multicenter Airway Research Collaboration
Recruiting now · Phase 4
Conditions studied: Asthma Acute, Asthma Exacerbation, Asthma, Asthma Control Level
In brief
The study is a randomized controlled trial on the effect of emergency department initiation of Airsupra on acute asthma "recurrence" at 3 months and other related outcomes (acute asthma relapse, asthma control).
Key facts
- Study ID
- NCT07166939
- Run by
- Massachusetts General Hospital
- People needed
- 1860
- Starts
- 2025-11-07
- Expected to finish
- 2027-06-01
- Last updated by the study team
- 2026-04-17
Who can join
Age: 18 and older, up to 54. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- acute asthma
- age 18.0 to 54.9 years
- English and/or Spanish speaking
- decision by ED attending to discharge patient to home on short course of systemic corticosteroids
- (intervention group only) Willingness to use Airsupra as their rescue inhaler for next 3 months
- demonstration of acceptable MDI administration technique
- provision of informed consent prior to any study-specific procedures
You may not qualify if…
- involvement in the planning and/or conduct of the study
- previous enrolment in the present study
- prior diagnosis of COPD, chronic bronchitis, or emphysema
- use of systemic corticosteroids in the past 2 weeks
- participation in another clinical study with an investigational product during the past 4 weeks or the 3 months after enrollment in the current study
- concurrent pneumonia
- clinically significant cardiovascular disease or clinically significant cancer
- patients with known hypersensitivity to Airsupra, albuterol sulfate, budesonide, or any of the excipients of the product
- (for women only, by self-report):
- currently pregnant
- currently breastfeeding,
- (among sexually active women of child-bearing age only) not using adequate contraception over the last 3 months, or no plan to use adequate contraception over the next 3 months
- lack of a working cell phone and working email address
- expected lack of availability for text and/or telephone follow-up at approximately 3, 6, and 12 weeks after the ED visit
- inability to provide an alternate contact with a working cell phone and working email address.
Where it is running
- MetroHealth — Cleveland, Ohio, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.